Dr. Dong-Wan Kim
Claim this profileSeoul National University Hospital
Area of expertise
Lung Cancer
Dong-Wan Kim has run 12 trials for Lung Cancer. Some of their research focus areas include:
Non-Small Cell Lung Cancer
Dong-Wan Kim has run 8 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:
Clinical Trials Dong-Wan Kim is currently running
GSK4381562
for Cancer
This trial tests a new drug called GSK4381562 in patients with recurring or spreading tumors who have no other treatment options. It will see how the drug is processed by the body, its safety, and any immune responses it might cause.
Recruiting
2 awards
Phase 1
3 criteria
Repotrectinib
for Solid Tumors
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with advanced solid malignancies harboring an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. Midazolam DDI substudy will examine effect of of repotrectinib on CYP3A induction. Phase 2 will determine the confirmed Overall Response Rate (ORR) as assessed by Blinded Independent Central Review (BICR) of repotrectinib in each subject population expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. The secondary objective will include the duration of response (DOR), time to response (TTR), progression-free survival (PFS), overall survival (OS) and clinical benefit rate (CBR) of repotrectinib in each expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement.
Recruiting
1 award
Phase 1 & 2
7 criteria
More about Dong-Wan Kim
Clinical Trial Related
4 years of experience running clinical trials · Led 17 trials as a Principal Investigator · 4 Active Clinical Trials
Treatments Dong-Wan Kim has experience with
- Dostarlimab
- Selpercatinib
- GSK4428859A
- Repotrectinib (TPX-0005)
- Ezabenlimab
- BI 836880
Breakdown of trials Dong-Wan Kim has run
Lung Cancer
- A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC
- GSK4381562 for Cancer
- The Purpose of Study is to Evaluate the Safety, Pharmacokinetics and Anti-tumor Effects of CKD-702 in Patients With Advanced or Metastatic Non-small Cell Lung Cancer Who Failed to Standard Therapy
Non-Small Cell Lung Cancer
- A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC
- The Purpose of Study is to Evaluate the Safety, Pharmacokinetics and Anti-tumor Effects of CKD-702 in Patients With Advanced or Metastatic Non-small Cell Lung Cancer Who Failed to Standard Therapy
- Selpercatinib for Non-Small Cell Lung Cancer
Solid Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Dong-Wan Kim specialize in?
Dong-Wan Kim focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is Dong-Wan Kim currently recruiting for clinical trials?
Yes, Dong-Wan Kim is currently recruiting for 3 clinical trials in Seoul Jongno-gu. If you're interested in participating, you should apply.
Are there any treatments that Dong-Wan Kim has studied deeply?
Yes, Dong-Wan Kim has studied treatments such as Dostarlimab, Selpercatinib, GSK4428859A.
What is the best way to schedule an appointment with Dong-Wan Kim?
Apply for one of the trials that Dong-Wan Kim is conducting.
What is the office address of Dong-Wan Kim?
The office of Dong-Wan Kim is located at: Seoul National University Hospital, Seoul, Jongno-gu 03080 Korea, Republic of. This is the address for their practice at the Seoul National University Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.